Compare Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery

Back to Search
Print
Bookmark Trial

NCT00150280

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Shenyang, Liaoning, 110001, China
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Postoperative Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Undergone uncomplicated orthopedic surgery or abdominal gynecological surgery under epidural anesthesia

- Baseline pain intensity of more than 45 mm as measured by VAS and a severity of pain graded as moderate or severe on the categorical pain intensity scale

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- A previous history of intolerance or hypersensitivity to any NSAIDs, cyclooxygenase
inhibitor, sulfonamides, or any analgesic, or to drugs with similar chemical
structures

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Postoperative PainAn Open-Label Safety Study Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain
NCT00726388
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Florence, Alabama
  4. Mobile, Alabama
  5. Montgomery, Alabama
  6. Montgomery, Alabama
  7. Sheffield, Alabama
  8. Peoria, Arizona
  9. Phoenix, Arizona
  10. Little Rock, Arkansas
  11. Bakersfield, California
  12. Glendale, California
  13. Laguna Hills, California
  14. Los Angeles, California
  15. Pasadena, California
  16. Santa Barbara, California
  17. Vista, California
  18. Aurora, Colorado
  19. Englewood, Colorado
  20. Steamboat Springs, Colorado
  21. Hartford, Connecticut
  22. Inverness, Florida
  23. Lauderdale Lakes, Florida
  24. Pensacola, Florida
  25. Tampa, Florida
  26. Decatur, Georgia
  27. Mooresville, Indiana
  28. Kansas City, Kansas
  29. Merriam, Kansas
  30. New Orleans, Louisiana
  31. Great Falls, Montana
  32. Albany, New York
  33. Staten Island, New York
  34. Columbus, Ohio
  35. Altoona, Pennsylvania
  36. Altoona, Pennsylvania
  37. Johnstown, Pennsylvania
  38. Johnstown, Pennsylvania
  39. Pittsburgh, Pennsylvania
  40. Pittsburgh, Pennsylvania
  41. Somerset, Pennsylvania
  42. State College, Pennsylvania
  43. Hendersonville, Tennessee
  44. San Antonio, Texas
  45. San Antonio, Texas
  46. Temple, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Postoperative PainEfficacy and Safety of IV Diclofenac (DIV075V)for Pain After Elective Orthopedic Surgery
NCT00507026
  1. Sheffield, Alabama
  2. Phoenix, Arizona
  3. San Clemente, California
  4. Fort Pierce, Florida
  5. Louisville, Kentucky
  6. Raleigh, North Carolina
  7. State College, Pennsylvania
  8. Austin, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Postoperative PainCompare Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery
NCT00150280
  1. Shenyang, Liaoning
  2. Beijing,
  3. Beijing,
  4. Beijing,
  5. Shanghai,
  6. Shanghai,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Postoperative PainEfficacy And Safety Of Parecoxib IV/IM 40 Mg Vs Placebo Following Sub Muscular Breast Augmentation
NCT00435747
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Compare Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery
Official Title  ICMJE A Prospective, Randomized, Double-Blind, Double-Dummy, Multi-Center Study Comparing Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery
Brief Summary To validate the analgesic efficacy and safety of celecoxib compared with ibuprofen SR in the management of acute pain post orthopedic or gynecological surgery
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Pain, Postoperative
Intervention  ICMJE Drug: celecoxib and ibuprofen SR
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: September 6, 2005)		132
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE July 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Undergone uncomplicated orthopedic surgery or abdominal gynecological surgery under epidural anesthesia
  • Baseline pain intensity of more than 45 mm as measured by VAS and a severity of pain graded as moderate or severe on the categorical pain intensity scale

Exclusion Criteria:

  • A previous history of intolerance or hypersensitivity to any NSAIDs, cyclooxygenase inhibitor, sulfonamides, or any analgesic, or to drugs with similar chemical structures
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00150280
Other Study ID Numbers  ICMJE A3191086
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. )
Study Sponsor  ICMJE Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP